UNSPSC 51451902: Flurantel

This classification denotes an antihelminthic agent with the molecular formula C19H12F6N2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q14SL1C0O, chemically known as 2,6-dihydroxy-3-nitro-3,5-bis(trifluoromethyl)benzanilide diacetate (ester). but generally known as flurantel, which bears US NIH Compound Identifier 219070. European Medicines Agency schedules Flurantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07743MIG.

UNSPSC 51451902 Flurantel, a Commodity code, shows minimal relevant state and local procurement activity aligned with its nominal scope. The recent opportunities tagged under this code involve naloxone and drug deactivation systems (Seminole County, Florida) and antibiotics purchased through a pharmaceutical piggyback contract (Illinois Department of Public Health), neither of which are flurantel products. State and local procurement offices appear to use this code inconsistently or not at all for its intended product category, instead applying it to broader pharmaceutical and medical supply categories. The issuing bodies in recent records are a county health department and a state health authority operating through cooperative purchasing arrangements, but the mismatch between code definition and actual procurement scope limits the relevance of these records to firms specializing in flurantel specifically.

The two most recent opportunities are geographically dispersed across Florida and Illinois. Seminole County released an IFB on June 30, 2026, for naloxone and drug deactivation systems with a response deadline of July 26, 2023, requiring quarterly deliveries and fixed-fee pricing on a two-year initial term with one-year renewal option. The Illinois Department of Public Health awarded a $2.999 million piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for antibiotics under an IFB process, with a 12-month initial term and renewal options for years two and three. Neither opportunity signals active pursuit of flurantel as a line item or category, and both appear to reflect general pharmaceutical supply procurement using an inaccurate or overly broad code assignment rather than targeted demand for the specific product.